Lub-de Hooge MN - Search Results

1

Modelling Tools to Characterize Acetaminophen Pharmacokinetics in the Pregnant Population.

Brookhuis SAM, Allegaert K, Hanff LM, Lub-de Hooge MN, Dallmann A, Mian P. Brookhuis SAM, et al. Among authors: lub de hooge mn. Pharmaceutics. 2021 Aug 20;13(8):1302. doi: 10.3390/pharmaceutics13081302. Pharmaceutics. 2021. PMID: 34452263 Free PMC article. Review.

2

The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease-A Systematic Literature Review.

Wiersma TK, Visschedijk MC, de Boer NK, Lub-de Hooge MN, Prins JR, Touw DJ, Mian P. Wiersma TK, et al. Among authors: lub de hooge mn. Pharmaceutics. 2022 Jun 11;14(6):1241. doi: 10.3390/pharmaceutics14061241. Pharmaceutics. 2022. PMID: 35745812 Free PMC article. Review.

3

Pharmacokinetic Boosting of Kinase Inhibitors.

Westra N, Touw D, Lub-de Hooge M, Kosterink J, Oude Munnink T. Westra N, et al. Pharmaceutics. 2023 Apr 5;15(4):1149. doi: 10.3390/pharmaceutics15041149. Pharmaceutics. 2023. PMID: 37111635 Free PMC article. Review.

4

Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.

Oude Munnink TH, de Vries EG, Vedelaar SR, Timmer-Bosscha H, Schröder CP, Brouwers AH, Lub-de Hooge MN. Oude Munnink TH, et al. Mol Pharm. 2012 Nov 5;9(11):2995-3002. doi: 10.1021/mp3002182. Epub 2012 Oct 11. Mol Pharm. 2012. PMID: 23003202

5

Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use.

Ter Weele EJ, Terwisscha van Scheltinga AG, Linssen MD, Nagengast WB, Lindner I, Jorritsma-Smit A, de Vries EG, Kosterink JG, Lub-de Hooge MN. Ter Weele EJ, et al. Eur J Pharm Biopharm. 2016 Jul;104:226-34. doi: 10.1016/j.ejpb.2016.05.008. Epub 2016 May 12. Eur J Pharm Biopharm. 2016. PMID: 27179587

6

Comparative biodistribution analysis across four different ⁸⁹Zr-monoclonal antibody tracers-The first step towards an imaging warehouse.

Bensch F, Smeenk MM, van Es SC, de Jong JR, Schröder CP, Oosting SF, Lub-de Hooge MN, Menke-van der Houven van Oordt CW, Brouwers AH, Boellaard R, de Vries EGE. Bensch F, et al. Theranostics. 2018 Jul 30;8(16):4295-4304. doi: 10.7150/thno.26370. eCollection 2018. Theranostics. 2018. PMID: 30214621 Free PMC article.

7

Preclinical characterisation of 111In-DTPA-trastuzumab.

Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de Jong S, Jager PL, de Vries EG. Lub-de Hooge MN, et al. Br J Pharmacol. 2004 Sep;143(1):99-106. doi: 10.1038/sj.bjp.0705915. Epub 2004 Aug 2. Br J Pharmacol. 2004. PMID: 15289297 Free PMC article.

8

Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.

Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M. Lub-de Hooge MN, et al. Ann Rheum Dis. 2005 Jun;64(6):854-8. doi: 10.1136/ard.2004.029058. Epub 2004 Nov 25. Ann Rheum Dis. 2005. PMID: 15564310 Free PMC article.

9

Molecular imaging: what can be used today.

Jager PL, de Korte MA, Lub-de Hooge MN, van Waarde A, Koopmans KP, Perik PJ, de Vries EG. Jager PL, et al. Cancer Imaging. 2005 Nov 23;5 Spec No A(Spec No A):S27-32. doi: 10.1102/1470-7330.2005.0023. Cancer Imaging. 2005. PMID: 16361133 Free PMC article. Review.

10

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG. Perik PJ, et al. J Clin Oncol. 2006 May 20;24(15):2276-82. doi: 10.1200/JCO.2005.03.8448. J Clin Oncol. 2006. PMID: 16710024

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

96 results

Search Page